[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@mike98572986 Avatar @mike98572986 mike

mike posts on X about $clpt, $qure, $rgnx, the first the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence cryptocurrencies XXXX% finance XXXX% countries XXXX% technology brands XXXX%

Social topic influence $clpt #1, $qure #4, $rgnx #6, the first 12.12%, rgx 121 #1, $par #21, to the 6.06%, $xpel 6.06%, ceo 6.06%, $33m XXXX%

Top accounts mentioned or mentioned by @desertdweller93 @micahc22 @stockdaddy6597 @lawstudentrm @profdollar @medstudentinvst @newinvest22 @kane_1200

Top assets mentioned uniQure N.V. (QURE) Parachute (PAR) Bitcoin Incognito (XBI)

Top Social Posts

Top posts by engagements in the last XX hours

"$clpt High probability of being a clearpoint partner EpilepsyGTx raises $33m Series A to develop single dose gene therapy for focal refractory epilepsy Paul Larson consults with them and Our approach is to deliver a single dose of gene therapy directly to the seizure focus in a surgical procedure that takes place in a hospital. During the procedure a very thin cannula with a diameter of about 1-2 millimetres (that is thinner than a grain of rice) is inserted into the seizure focus to deliver a volume of about X millilitre (or ml) of gene therapy as shown in Figure X below. Importantly our"
X Link 2025-12-09T23:39Z 1171 followers, 1174 engagements

"$clpt Ohio state If it has the ability to reverse disease that changes the lives of millions of people in the United States overnight. It would completely reshape how we think about disease Dr. Lonser says. Paired with the discovery of another researcher who has now joined him at Ohio State its a once-in-a-generation breakthrough that could represent the holy grail for todays neurological field potentially giving surgeons the ability to cure conditions like Alzheimers diseaseand Parkinsons diseaseby delivering growth-factor genes to rescue dying brain cells. About a dozen trials are in"
X Link 2025-12-10T15:02Z 1171 followers, XXX engagements

"$xpel I missed that Alta Fox bought a big position in Xpel they have been in and out on the name over the years but last 13f basically had a tracking position on and now XXX percent of the company"
X Link 2025-12-09T07:59Z 1171 followers, XXX engagements

"$clpt new study Stereotactic Accuracy and Technique Utilizing the SmartFrame OR Platform with Stereotactic Navigation and Conebeam CT Image-Guided Forward Projection This retrospective study analyzed XX patients (33 procedures) undergoing DBS electrode placement using the SmartFrame OR system (ClearPoint Neuro Inc. San Diego CA). Radial targeting error and operative duration were assessed. Conclusion The ClearPoint SmartFrame OR system achieved submillimeter accuracy and operational efficiency comparable to MRI-guided platforms while eliminating MRI dependency. Its integration with O-arm and"
X Link 2025-12-10T22:48Z 1171 followers, XXX engagements

"$clpt $qure $rgnx CEO of Regenxbio hits the nail on the head at 8:40 Money quote I think what we have learned from these other approvals and launches is it is not just enough to get approval it has to be a value proposition that makes sense. A lot of that has to do with just not how big a market is or what type of benefit you could achieve it is how does it compare to what exists I think that is the problem that other programs in the cell based therapies have run into is making that transition. It is not a marginal improvement that we are talking about compared to existing therapies - it is"
X Link 2025-07-05T07:49Z 1171 followers, 5697 engagements

"$clpt $rgnx RGX-121 "I am highly encouraged by the 12-month pivotal data and continued safety and efficacy profile of RGX-121" said Roberto Giugliani M.D. Ph.D. ProfessorDepartment of Genetics UFRGS Medical Genetics Service HCPAPorto Alegre Brazil."The vast majority of Hunter syndrome patients have no current treatment options to address the neurodevelopmental decline of this disease and are in urgent need of new therapies and a one-time treatment option like RGX-121 could make a meaningful impact on their lives.""
X Link 2025-09-05T15:00Z 1172 followers, 2126 engagements

"$par Erbert & Gerberts Transforms Operations with PARs Unified Restaurant Platform New POS payments delivery loss recovery and menu management solutions streamline complexity and boost efficiency across XX locations"
X Link 2025-11-20T15:39Z 1172 followers, XXX engagements

"If These quotes are true VP might not be the problem very odd public statements if these are his true thoughts. If these are true I dont believe he is going to ask for a whole new trial $qure $clpt"
X Link 2025-12-05T15:00Z 1170 followers, 3510 engagements

"$qure $clpt What a odd situation this has been on one hand Makary and VP sound rational and good for gene therapies on their public statements seems their words have been hot air mostly actions havent really held up on the other hand if they get fired you also have to ask who is next. At this point I guess you take your chance with some new characters. I do wish we had more insight on what the fda is saying to Uniqure because if the hold up is just they want more patients at the X year and X year mark that isnt really a irrational thing. I havent been a fan of VP but his point about trying to"
X Link 2025-12-06T01:24Z 1170 followers, 3185 engagements

"Adds today $Dcth and $par Really liking par tech down here"
X Link 2025-09-30T16:19Z 1172 followers, 1794 engagements

"$xpel Market is still sleeping on Xpel these guys dont care whether we are in a crap car market or a roaring car market they will continue to push forward and gain market share with new products partnerships and territories. Pape is a CEO that you can count on to do the right thing very few companies that you can completely trust leadership this is one of them"
X Link 2025-10-18T15:04Z 1172 followers, 1574 engagements

"$par is a funny one does anyone truly believe Olo was a better company than Par tech You have a recent comp Olo got bought out at X billion I dont believe Olo was anywhere near Par in the type of position they are in. Par also has a catalyst set up market gives you opportunities because they cant see past one quarter. That is all analysts care about what does the next quarter look like Its kind of cool for investors that actually can just chill and are willing to sit on their ass. Fun times"
X Link 2025-10-21T15:14Z 1172 followers, 1419 engagements

"$clpt rgx XXX cc $RGNX Now to RGX-121 also known as chlamidiginelamparvovec the potential first gene therapy and one-time treatment for MPS II. Our recent FDA interactions regarding the ongoing BLA have been highly productive and we remain confident in RGX-121 approval by early next year. We delivered positive 12-month data to FDA which Steve will discuss in more detail. And the FDA completed inspections of our clinical sites and in-house manufacturing facility with no observations a rare and significant achievement. These developments have further strengthened our confidence in the ongoing"
X Link 2025-11-08T15:38Z 1172 followers, 1502 engagements

"$clpt rgx XXX $rgnx conference today Got it. So in the last few minutes I want to touch on the Hunter Syndrome program. The FDA requested some additional information. Where are you in that process right now And do you think that's going to be a major amendment Already has been. So we were asked in our mid-cycle meeting sort of in August timeframe of last year to provide we had provided six-month data on the patients for neurocog development. And by the time we had completed the rolling VLA I think FDA looked at the dosing dates and knew we would have one year's worth of data. So we supplied"
X Link 2025-11-10T23:32Z 1171 followers, 1633 engagements

"$clpt rgx XXX $rgnx conference yesterday transcript This is going to be the first gene therapy for Hunter's disease and it's in a market that is completely served by enzyme replacement therapy. Even though there is an enzyme replacement therapy that's presumably in development that could cross the blood brain barrier you have the potential to potentially go in there and disrupt it. Though Denali is sitting at a $X billion valuation you guys are sitting around a $XXX million-$600 million valuation. I guess how should we think about this disconnect number one. And number two how do you think"
X Link 2025-11-12T11:31Z 1172 followers, 1237 engagements

"$clpt minute XX same delivery on all programs AS first patient dosed last week. If Rgx XXX gets approved in February makes all these programs a lot more attractive from there"
X Link 2025-11-18T00:25Z 1172 followers, 2069 engagements

"$qure $clpt Staveley has not had the treatment but says that if it gets to the point she needs it and it is available she would leap at the chance: I struggle to imagine the impact this will have on my life let alone the impact on those who have already developed symptoms. I went to Hyde Park and just cried and cried Staveley recalls. For the first time I thought this is a real breakthrough. I felt I have a future. Id had this sword of Damocles over me always thinking whens the disease going to strike Staveley thought of her son Alexander known as Lexi who has just turned 11: The most"
X Link 2025-12-07T00:51Z 1172 followers, 6722 engagements

"@micahc22 @StockDaddy6597 RGX-121 and KEBILIDI"
X Link 2025-12-07T15:09Z 1172 followers, XX engagements

"$clpt $qure UniQure received FDAs meeting minutes on AMT-130. While there were no new updates the communitys response has been powerful with 41K+ petition signatures & unified advocacy from major HD orgs. In response to this challenging moment major HD advocacy organizations have come together to issue a Statement of Unity (see More Info section below). Help4HD HDReach Huntingtons Disease Society of America Huntingtons Disease Foundation and the Huntingtons Disease Youth Organization have pledged to work in partnership to champion the voices of those impacted by HD particularly when"
X Link 2025-12-08T19:48Z 1171 followers, 11.4K engagements

"$clpt This is the first reported case documenting the use of DBS targeting the pulvinar for acute NORSE where cessation of status epilepticus was achieved through continuous pulvinar stimulation after implantation combined with conventional therapies. This case highlights the potential utility of tailoring thalamic neuromodulatory targets such as the pulvinar to the individual's epileptogenic networkparticularly in posterior onsetwhile acknowledging the established roles of ANT and CMT in other localizations. Bilateral Medtronic SenSight DBS electrodes were placed with the assistance of"
X Link 2025-12-10T22:51Z 1171 followers, XXX engagements